Influence of long-term physical activity on serum PCSK9, HDL/LDL-cholesterol and lipoprotein a-levels

被引：0
|
作者：
Sponder, M. [1 ]
Campean, I. A. [1 ]
Dalos, D. [1 ]
Emich, M. [2 ]
Fritzer-Szekeres, M. [3 ]
Litschauer, B. [4 ]
Bergler-Klein, J. [1 ]
Graf, S. [1 ]
Strametz-Juranek, J. [1 ]
机构：
[1] Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Vienna, Austria
[2] Med Univ Vienna, Fed Minist Def & Sports, Vienna, Austria
[3] Univ Vienna, Dept Med & Chem Lab Diagnost, Vienna, Austria
[4] Med Univ Vienna, Clin Pharmacol, Vienna, Austria
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1516
引用
收藏
页码：315 / 315
页数：1
相关论文
共 50 条
  • [1] Influence of long-term physical activity on serum PCSK9, HDL/LDL-cholesterol and lipoprotein a-levels
    Sponder, M.
    Campean, I. -A.
    Dalos, D.
    Emich, M.
    Fritzer-Szekeres, M.
    Litschauer, B.
    Bergler-Klein, J.
    Graf, S.
    Strametz-Juranek, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : S85 - S86
  • [2] PCSK9—an exciting target for reducing LDL-cholesterol levels
    D. John Betteridge
    Nature Reviews Endocrinology, 2013, 9 : 76 - 78
  • [3] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [4] Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial
    Sponder, Michael
    Campean, Ioana-Alexandra
    Dalos, Daniel
    Emich, Michael
    Fritzer-Szekeres, Monika
    Litschauer, Brigitte
    Bergler-Klein, Jutta
    Graf, Senta
    Strametz-Juranek, Jeanette
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (7-8): : 506 - 511
  • [5] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [6] The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
    Piper, Derek E.
    Jackson, Simon
    Liu, Qiang
    Romanow, William G.
    Shetterly, Susan
    Thibault, Stephen T.
    Shan, Bei
    Walker, Nigel P. C.
    STRUCTURE, 2007, 15 (05) : 545 - 552
  • [7] LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors
    Luscher, Thomas F.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1337 - 1340
  • [8] Long-Term Efficacy of Very Low LDL-Cholesterol Levels With the PCSK9 Inhibitor Evolocumab: Analysis of the FOURIER and FOURIER-OLE Studies
    Gaba, Prakriti
    O'Donoghue, Michelle L.
    Park, Jeong-Gun
    Wiviott, Stephen D.
    Atar, Dan
    Keech, Anthony
    Kuder, Julia
    Im, KyungAh
    Murphy, Sabina A.
    Flores-Arredondo, Jose H.
    Lopez, J. Antonio G.
    Elliott-Davey, Mary
    Wang, Bei
    Monsalvo, Maria L.
    Abbasi, Siddique
    Giugliano, Robert P.
    Sabatine, Marc S.
    CIRCULATION, 2022, 146 (25) : E604 - E604
  • [9] Plasma PCSK9 Levels Are Positively Correlated With LDL-Cholesterol Concentrations in Familial Hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Hogue, Jean-Charles
    Ooi, Teik C.
    Lamarche, Benoit
    Couture, Patrick
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34
  • [10] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
12345